Bayer has taken another step toward achieving its €3 billion peak sales estimate for androgen receptor inhibitor Nubeqa, ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

CompanyOverview\|NYSE:PFE] A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. (NYSE: PFE) certainly catches the eye of income- ...

(RTTNews) - Astellas Pharma Inc. (ALPMY) and Pfizer Inc. (PFE ... risk of death in men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with XTANDI (enzalutamide), an androgen ...

Former President Joe Biden has been diagnosed with an "aggressive" form of prostate cancer that has spread to his bones. But what does it mean for this type of cancer to be called aggressive?

"The survival benefits of intervention with XTANDI in advanced prostate ... About Pfizer Oncology At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading ...

is the first and only androgen receptor inhibitor to demonstrate an overall survival benefit at five years in men with metastatic hormone-sensitive prostate cancer Data continue to show wide ...

TOKYO and NEW YORK, May 22, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc ... sensitive prostate cancer (mHSPC) treated ...

Pfizer is aiming to expand Talzenna’s existing prostate cancer nod—in combination with its Astellas-partnered androgen receptor inhibitor Xtandi—beyond the HRR mutant population where it’s ...